Baret News – Lifestyle
Author:
BioAge Labs, Inc.
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
April 21, 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
April 13, 2026
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026